楊先達

楊先達課題組目前有助理研究員一名，主任技師一名，研究生和進(jìn)修生多名；有兩個(gè)主要的科研方向：納米技術(shù)的醫學(xué)應用和腫瘤靶向分子的開(kāi)發(fā)研究。

楊先達教授為協(xié)和醫科大學(xué)醫學(xué)博士、美國紐約州立大學(xué)理學(xué)博士和美國內科醫師，既往曾任美國斯坦福大學(xué)博士后研究員、美國羅氏藥廠(chǎng)科學(xué)家、美國法瑪西藥廠(chǎng)亞洲區醫學(xué)總監、美國硅谷圣何西醫學(xué)中心主治醫師等職，具備基礎科研、臨床研究和臨床醫療方面的豐富經(jīng)驗。在基礎科研方面，成果曾發(fā)表于自然雜志(Nature)等國際學(xué)術(shù)刊物；在臨床研究方面，曾設計和參與多項呈交美國FDA審批的國際性臨床藥物試驗；在臨床醫療方面，具美國行醫執照和多年臨床經(jīng)驗。回國后將碳納米技術(shù)應用于抗腫瘤免疫療法并取得了國際領(lǐng)先的科研成果，在腫瘤靶向分子的研發(fā)方面也有扎實(shí)的進(jìn)展。

近年發(fā)表論文：

[1] Sun Zhao,Liu Zhe, Meng Jie, Meng Jie,Duan Jinhong,Xie Sishen,Lu Xin,Zhu Zhaohui,Wang Chen,Shuchang,Xu Haiyan,Yang Xian-Da

Carbon Nanotubes Enhance Cytotoxicity Mediated by Human Lymphocytes

In Vitro(2011) Plosone, 6(6), pp 21073-21081

[2] Chenchen Yu,Yan Hu,Jinhong Duan, Xianda Yang

Novel Aptamer-Nanoparticle Bioconjugates Enhances Delivery of

Anticancer Drug to MUC1-Positive Cancer Cells In Vitro(2011) Plosone,

6(9), pp 24077-24085

[3]  Liu Zhe,Jinhong Duan,YongMei Song,Jie Ma,Fengda Wang,Xin Lu, Xian-DaYang

Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug to HER2-positive Breast Cancer Cells in Vitro.J Transl Med, (2012) Jul 20; 10, 148-158

[4] Yan Hu, Jinhong Duan, Qimin Zhan,FengDan Wang,Xin Lu, Xian-Da Yang

Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer

 cells in vitro.Plosone (2012)7（2）31970-31980

[5] Liang Zhang, Sun Zhao,Jinhong Duan,Ning Gu,Haiyan Xu,Xian-da Yang

Enhancement of DC-mediated anti-leukemic immunity in vitro by WT1

antigen and CpG co-encapsulated in PLGA microparticles  Protein &

Cell, (2013)13(3916), pp 1-3,

[6] Beibei Cao, Yan Hu, Jinhong Duan, Jie Ma, Danke Xu, Xian-Da Yang

Selection of a Novel DNA Aptamer for Assay of Intracellular

Interferon-Gamma (2014) PLoS ONE 9(5): e98214.

[7] Wei Wang, Zhongjun Li, Jinhong Duan, Chen Wang, Ying Fang, and Xian-Da Yang

    In vitro enhancement of dendritic cell-mediated anti-glioma immune

response by graphene oxide Nanoscale Research Letters （2014）, 9:311 

[8] Lianyuan Yu, Yan Hu, Jinhong Duan, and Xian-Da Yang

 A Novel Approach of Targeted Immunotherapy against Adenocarcinoma Cells

 with Nanoparticles Modified by CD16 and MUC1 Aptamers（2015）

Journal of Nanomaterials ( Article ID 316968 p1-10 Hindawi Publishing Corporation)

[9]Hu Yan，J Duan，B Cao，L Zhang，X Lu，Xian-Da Yang

Selection of a Novel DNA Thioaptamer against HER2 Structure

Clinical & translational oncology (2015), 17(8):págs. 647-656

 [10]Guo Fangqin，Y Hu，L Yu，X Deng，J Meng，Xian-Da Yang

Enhancement of Thermal Damage to AdenocarcinomaCells by Iron

Nanoparticles Modified with MUC1 Aptamer

Joural of Nanoscience and nanotechnology (2016)，16(3):2246-2253

[11] Dai Bindong Hu yan Duan Jinhong, Yang xianda

Aptamer-guided DNA tetrahedron as a novel targeted drug delivery system

for muc1-expressing breast cancer cells in vitro  Oncotarget (2016) Jun 21;7(25):38257-38269

[12]Meng Jie, Fangqin Guo, Haiyan Xu, Wei Liang, Chen Wang, Xian-Da Yang

Combination Therapy using Co-encapsulated Resveratrol and Paclitaxel in

Liposomes for Drug Resistance Reversal in Breast Cancer Cells in

Vivo (2016) 6:1-11 

近年獲得專(zhuān)利：

1. HER2蛋白核酸適配子、復合體、組合物及其用途（專(zhuān)利號：201210044833.9）

2. MUC1蛋白核酸適配子、復合體、組合物及其用途（專(zhuān)利號：201110425169.8）